Login to Your Account

Vicuron Files For Approval Of Drug For Esophageal Candidiasis

By Kim Coghill

Tuesday, April 29, 2003
Vicuron Pharmaceuticals Inc. filed a new drug application for its lead product, anidulafungin, an antifungal agent for the treatment of esophageal candidiasis, an infection of the esophagus that commonly affects patients with compromised immune systems. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription